Trial Profile

Novel Exploratory Study to Test Combination of Botensilimab and Balstilimab Immunotherapy in Resectable Colorectal Cancer Patients

Status: Suspended

Phase of Trial: Phase II

Latest Information Update: 12 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Balstilimab (Primary) ; Botensilimab (Primary)
Indications Adenocarcinoma; Colorectal cancer
Focus Adverse reactions; Therapeutic Use
Acronyms NEST-1; NEST-2

Most Recent Events

30 Jul 2025 Planned End Date changed from 1 Dec 2025 to 1 Jun 2026.
30 Jul 2025 Planned primary completion date changed from 1 May 2025 to 1 Nov 2025.
30 Jul 2025 Status changed from recruiting to suspended as temporarily paused to review safety data.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com